Breast Cancer Subtype Characterization Through Patient's Derived Organoids.

Recruiting now

Conditions studied: Breast Cancer, Organoids

In brief

Development of tools to predict patients chemo-sensitivity and identification of corresponding biomarkers is an urgent challenge for BC patients lacking targeted therapies, such as TNBC, or for patients experiencing relapse after adjuvant chemotherapy or targeted therapies. The refinement of 3D-cultivation techniques, experienced in the last decade, has allowed cultivation of patients-derived cancer cells in organotypic structures, named patient-derived organoids (PDO), which preserve histologic, genomic and transcriptomic features of primary tumors. PDO allow propagation, pharmacological treatment and genetic manipulation of patients-derived cancer cells in a close to physiology setting, thus representing a promising tool in the development of personalized therapies

Key facts

Study ID

NCT06315868

Run by

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

People needed

306

Starts

2023-06-15

Expected to finish

2027-06-15

Last updated by the study team

2024-03-18

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• women diagnosed with primary BC, eligible for surgical resection of the tumor according to national and international guidelines.
• age between 18 and 70 years; newly diagnosed breast neoplasms, tumor size of at least 1.5 cm diameter.

You may not qualify if…

• breast cancer diagnosed during pregnancy, neoadiuvant chemotherapy

Where it is running

• IRCCS Fondazione Policlinico A. Gemelli — Roma, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.